- Home
- ALKS vs MRUS Comparison
ALKS vs MRUS Comparison
Compare ALKS & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALKS
- MRUS
- Stock Information
- Founded
- ALKS 1987
- MRUS 2003
- Country
- ALKS Ireland
- MRUS Netherlands
- Employees
- ALKS N/A
- MRUS N/A
- Industry
- ALKS Biotechnology: Pharmaceutical Preparations
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- ALKS Health Care
- MRUS Health Care
- Exchange
- ALKS Nasdaq
- MRUS Nasdaq
- Market Cap
- ALKS 5.0B
- MRUS 5.1B
- IPO Year
- ALKS 1991
- MRUS 2016
- Fundamental
- Price
- ALKS $29.21
- MRUS $94.63
- Analyst Decision
- ALKS Strong Buy
- MRUS Buy
- Analyst Count
- ALKS 13
- MRUS 18
- Target Price
- ALKS $42.54
- MRUS $93.72
- AVG Volume (30 Days)
- ALKS 2.1M
- MRUS 3.5M
- Earning Date
- ALKS 10-28-2025
- MRUS 10-31-2025
- Dividend Yield
- ALKS N/A
- MRUS N/A
- EPS Growth
- ALKS 21.99
- MRUS N/A
- EPS
- ALKS 2.08
- MRUS N/A
- Revenue
- ALKS $1,505,296,000.00
- MRUS $56,228,000.00
- Revenue This Year
- ALKS N/A
- MRUS $51.77
- Revenue Next Year
- ALKS $1.59
- MRUS N/A
- P/E Ratio
- ALKS $14.32
- MRUS N/A
- Revenue Growth
- ALKS N/A
- MRUS 59.77
- 52 Week Low
- ALKS $25.17
- MRUS $33.19
- 52 Week High
- ALKS $36.45
- MRUS $95.06
- Technical
- Relative Strength Index (RSI)
- ALKS 42.95
- MRUS 79.42
- Support Level
- ALKS $29.94
- MRUS $94.40
- Resistance Level
- ALKS $32.02
- MRUS $95.06
- Average True Range (ATR)
- ALKS 1.13
- MRUS 0.32
- MACD
- ALKS -0.32
- MRUS -1.00
- Stochastic Oscillator
- ALKS 9.12
- MRUS 44.16
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.